These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7888196)

  • 1. Reactivity of AIDS patient sera with a peptide derived from HIV type 1NY5 glycoprotein 120 V3 loop and consensus sequence of collagens.
    Metlas R; Skerl V; Pongor S; Colombatti A; Veljković V
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1425-6. PubMed ID: 7888196
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.
    Schreiber M; Petersen H; Wachsmuth C; Müller H; Hufert FT; Schmitz H
    J Virol; 1994 Jun; 68(6):3908-16. PubMed ID: 8189527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
    Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
    Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120.
    Baillou A; Brand D; Denis F; M'Boup S; Chout R; Goudeau A; Barin F
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1209-15. PubMed ID: 7511395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
    Schreiber M; Wachsmuth C; Müller H; Hagen C; Schmitz H; van Lunzen J
    J Gen Virol; 1996 Oct; 77 ( Pt 10)():2403-14. PubMed ID: 8887471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on serologic reactivity of P-to-W substitution in the apex of the V3 loop of the HIV-1 subtype B glycoprotein.
    Vanden Haesevelde M; DeLeys RJ; Van Geel A; Vanderborght B; de Sá M; Van Eynde G; Saman E
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jan; 17(1):91-2. PubMed ID: 9436765
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetically engineered HIV type 1 peptides as tools for the determination of anti-V3 loop antibody titers in sera from HIV type 1-infected patients.
    Von Brunn A; Reichhuber C; Pfaff E; Wizemann H
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1459-65. PubMed ID: 8679289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides.
    Lawoko A; Johansson B; Dash R; Falck L; Dietrich U; Pipkorn R; Nilehn B; Blomberg J
    J Infect Dis; 1995 Sep; 172(3):682-90. PubMed ID: 7658059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin-like domain of HIV-1 envelope glycoprotein gp120 encodes putative internal image of some common human proteins.
    Metlas R; Skerl V; Veljkovic V; Colombatti A; Pongor S
    Viral Immunol; 1994; 7(4):215-9. PubMed ID: 7576036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS.
    Page M; Vella C; Corcoran T; Dilger P; Ling C; Heath A; Thorpe R
    AIDS; 1992 May; 6(5):441-6. PubMed ID: 1616648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping.
    Hoelscher M; Hanker S; Barin F; Cheingsong-Popov R; Dietrich U; Jordan-Harder B; Olaleye D; Nägele E; Markuzzi A; Mwakagile D; Minja F; Weber J; Gürtler L; Von Sonnenburg F
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):139-49. PubMed ID: 9462924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.